NMN (β-Nicotinamide Mononucleotide)

NMN does not have a documented history of significant consumption before 15 May 1997, so it is treated as a novel food that needs authorisation. In Great Britain the FSA has not authorised NMN — it is not on the GB authorisations register, and a determination has not been made; products linked to an in-process application may remain on the market under the transitional arrangements while that decision is pending. In the EU the position moved in 2026: EFSA's expert panel adopted a positive safety opinion on an applicant's β-NMN, judging up to 300 mg/day safe for adults other than during pregnancy and lactation and looking at how well nicotinamide is absorbed from it. That opinion is about safety, not about proving a benefit, and a European Commission authorisation decision is still pending. Whatever happens, no health claim is permitted on NMN in the UK. Camden Medicals stocks NMN under transparent disclosure of this status; the position is moving and is tracked on the encyclopaedia review schedule.

There are no human lifespan-outcome trials for NMN. Most of the popular framing extrapolates from animal data, which is older, partly contested, and has not been translated into human clinical outcomes. UK food-supplement claims for rejuvenation or lifespan-extension are not permitted on NMN. If you choose to supplement, the realistic framing is exploratory: NAD+ markers may rise; clinical impact is not established.

NR (nicotinamide riboside) is GB-authorised as a novel food via a separate authorisation. NMN is on the novel-food register as "pending" — under assessment. The two molecules are closely related precursors to NAD+ and the in-vivo endpoints (blood NAD+ rise) are similar in magnitude across the small trials of each. From a UK regulatory standpoint they are not interchangeable as products, even though the biochemistry is closely related. Neither has authorised UK food-supplement health claims.

NMN is converted to NAD+, which is then consumed and ultimately cleared back to nicotinamide. The clearance step via nicotinamide N-methyltransferase (NNMT) uses a methyl group from S-adenosyl methionine (SAM). High NAD+ flux therefore depletes the methyl pool. TMG (betaine) is a direct methyl-group donor that regenerates methionine from homocysteine, buffering the methyl pool. The pairing is mechanistic; outcome-trial evidence for the combination as such is limited. Camden NB-161 includes both at the commonly-cited literature ratio (500 mg NMN + 600 mg TMG).

No. NMN has not been studied in pregnancy or lactation, sits on the novel-food register as "pending" (no authorised UK consumption history), and includes no human safety data in these populations. Avoid in pregnancy and lactation. If you are trying to conceive, talk to your GP before supplementing.

Talk to the team managing your care first. NAD+ metabolism is relevant in cancer biology; NMN supplementation in active oncology should not be self-initiated. The conservative position in the absence of clinical-trial data is to defer to your oncology team.

Longer than most people give it, and the honest answer is that nobody has measured the thing you are probably asking about. The shortest interval any NMN trial has reported is eight days, and what moved was a blood marker (NAD), not how anyone felt: Pencina 2023 gave 1,000 mg of an investigational trial preparation (MIB-626) for fourteen days and measured a rise at days 8 and 14. The larger dose-ranging trial, Yi 2022, took its first measurement at day 30 and its second at day 60. So a few days is not a short trial — it is shorter than the first measurement in any study that exists. Two things follow. First, if you notice something within a day or two, NMN's NAD pathway is not the likely explanation; a change that fast is more plausibly the vitamin B12 in a combination product, a change in when or what you eat, or simply the ordinary day-to-day variation you would have had anyway. Second, longer is not a promise either — Akasaka 2022 gave 250 mg daily for twenty-four weeks to older men with diabetes and found no improvement in grip strength or walking speed. If you are going to try it, four to eight weeks at a consistent dose and time is a fair test; if there is nothing by then, stopping is a reasonable decision and not a failure of patience. ^[5,6,7]

Stop taking it, and tell us — the second part matters as much as the first. Camden is a food business, so we keep a record of every reaction a customer reports and review it against the product specification; that record is the only way a pattern across several people becomes visible instead of staying as several people's private experience. Email [email protected] with what you took, how much, for how long, and what you noticed. If the effect is severe, or you are on prescribed medication, speak to a pharmacist, your GP, or NHS 111 first — we are not able to give you clinical advice about your own case, and we should not try. On the commercial side: you have a legal right to cancel within fourteen days of receiving an order, and any subscription can be paused or cancelled from your account or by emailing us. Supplements that have been opened cannot normally be resold, so our published policy does not accept them back as standard returns — but tell us what happened rather than assuming the answer, because a reported reaction is not an ordinary change of mind and we do not treat it as one.